VERA · Vera Therapeutics, Inc. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-02 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. |
Stock Option (Right to Buy)
|
18,500 |
| 2026-09-02 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Convert↑
|
Class A Common Stock
|
18,500 |
| 2026-09-02 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.34, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
18,500 |
| 2026-08-03 | Boman Nancy Lee |
Chief Regulatory Officer |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. 1/4th of the RSUs, rounded to the nearest whole share, vest on each of August 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. |
Class A Common Stock
|
44,987 |
| 2026-08-03 | Boman Nancy Lee |
Chief Regulatory Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
12/48ths of the shares subject to the stock option will vest and become exercisable on August 3, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. |
Stock Option (right to buy)
|
63,011 |
| 2026-07-07 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Convert↑
Filing footnotes — Class A Common Stock (Direct)
This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
46,250 |
| 2026-07-07 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
2,200 |
| 2026-07-07 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. |
Stock Option (Right to Buy)
|
46,250 |
| 2026-07-07 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
32,550 |
| 2026-07-07 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
10,500 |
| 2026-07-07 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
1,000 |
| 2026-06-23 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
88 |
| 2026-06-23 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. |
Stock Option (Right to Buy)
|
18,500 |
| 2026-06-23 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.315, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
18,412 |
| 2026-06-23 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Convert↑
Filing footnotes — Class A Common Stock (Direct)
This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
18,500 |
| 2026-05-21 | MORRISSEY MICHAEL |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Stock Option (right to buy)
|
17,084 |
| 2026-05-21 | Hall Kimball |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Stock Option (right to buy)
|
17,084 |
| 2026-05-21 | Meyers James R |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Stock Option (right to buy)
|
17,084 |
| 2026-05-21 | Morrison Scott W |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Stock Option (right to buy)
|
17,084 |
| 2026-05-21 | Cheng Andrew |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Stock Option (right to buy)
|
17,084 |
| 2026-05-21 | Oliger Christy J. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Stock Option (right to buy)
|
17,084 |
| 2026-05-21 | ENRIGHT PATRICK G |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Stock Option (right to buy)
|
17,084 |
| 2026-05-21 | SEIDENBERG BETH C |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Stock Option (right to buy)
|
17,084 |
| 2026-05-12 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Convert↑
Filing footnotes — Class A Common Stock (Direct)
This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
18,500 |
| 2026-05-12 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. |
Stock Option (Right to Buy)
|
18,500 |
| 2026-05-12 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
14,219 |
| 2026-05-12 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". |
Class A Common Stock
|
4,281 |
| 2026-04-14 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.25 to $45.20, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
7,921 |
| 2026-04-14 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.25 to $45.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
900 |
| 2026-04-14 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.25 to $44.24, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Includes 1,032 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2026. |
Class A Common Stock
|
14,130 |
| 2026-03-23 | Wright-Mitchell Jane |
Chief Legal Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
12/48ths of the shares subject to the stock option will vest and become exercisable on March 23, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. |
Stock Option (right to buy)
|
56,850 |
| 2026-03-23 | Wright-Mitchell Jane |
Chief Legal Officer |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of May 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. |
Class A Common Stock
|
42,403 |
| 2026-03-13 | Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
Convert↑
Filing footnotes — Class A Common Stock (Direct)
Includes 1,032 shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan. |
Class A Common Stock
|
10,000 |
| 2026-03-13 | Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter. |
Stock Option (right to buy)
|
10,000 |
| 2026-03-05 | Hite Christopher |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to the option will vest monthly over a three-year period, subject to the Reporting Person's continuous service on each vesting date. |
Stock Option (right to buy)
|
24,937 |
| 2026-02-23 | Brenner Robert |
Chief Medical Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
2,151 |
| 2026-02-23 | JOHNSON DAVID LEE |
Chief Operating Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
2,579 |
| 2026-02-23 | Skelton Laurence Matthew |
Chief Commercial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
1,582 |
| 2026-02-23 | Grant Sean |
CHIEF FINANCIAL OFFICER |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
4,949 |
| 2026-02-23 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
16,925 |
| 2026-02-23 | Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
3,117 |
| 2026-02-23 | Turner William D. |
Chief Regulatory Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Class A Common Stock
|
2,187 |
| 2026-02-04 | Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. |
Class A Common Stock
|
10,000 |
| 2026-02-04 | Brenner Robert |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. |
Stock Option (right to buy)
|
50,000 |
| 2026-02-04 | JOHNSON DAVID LEE |
Chief Operating Officer |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. Includes 643 shares of Class A Common Stock acquired on March 13, 2025 and 763 shares of Class A Common Stock acquired on September 12, 2025 under the Issuer's 2021 Employee Stock Purchase Plan. |
Class A Common Stock
|
20,000 |
| 2026-02-04 | Skelton Laurence Matthew |
Chief Commercial Officer |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. |
Class A Common Stock
|
20,000 |
| 2026-02-04 | Turner William D. |
Chief Regulatory Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. |
Stock Option (right to buy)
|
50,000 |
| 2026-02-04 | Grant Sean |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. Includes 893 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on September 12, 2025. |
Class A Common Stock
|
25,000 |
| 2026-02-04 | Fordyce Marshall |
Director, PRESIDENT AND CEO |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. Includes 623 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2025. |
Class A Common Stock
|
68,800 |
| 2026-02-04 | Brenner Robert |
Chief Medical Officer |
Award↑
Filing footnotes — Class A Common Stock (Direct)
Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. Includes 624 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2025. |
Class A Common Stock
|
25,000 |